García Patricia, Guijarro-Sánchez Paula, Lasarte-Monterrubio Cristina, Muras Andrea, Alonso-García Isaac, Outeda-García Michelle, Maceiras Romina, Fernández-López María Del Carmen, Rodríguez-Coello Arianna, García-Pose Andrea, Blanco-Martín Tania, González-Pinto Lucía, Arca-Suárez Jorge, Vázquez-Ucha Juan C, Bou Germán, Beceiro Alejandro
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain; Ciber de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
Servicio de Microbiología and Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain.
Biomed Pharmacother. 2024 Dec;181:117666. doi: 10.1016/j.biopha.2024.117666. Epub 2024 Dec 2.
The rise in multidrug-resistant bacteria challenges clinical microbiology. Tigecycline, eravacycline, and omadacycline show promise against carbapenem-resistant Enterobacterales and Acinetobacter baumannii. This study evaluates their activity and resistance mechanisms.
Two Spanish multicentre collections of WGS-characterized carbapenemase-producing Enterobacterales (n=399) and A. baumannii (n=118) were tested. The MICs of tigecycline, eravacycline, omadacycline and classic tetracyclines were determined. WGS-guided resistome analysis, expression studies, efflux pump inhibition and cloning assays identified potential mechanisms of resistance.
Tigecycline and eravacycline exhibited the highest activity against the whole set of Enterobacterales (MIC/MIC 0.5/1 mg/L and 1/2 mg/L, respectively), and A. baumannii (MIC/MIC 1/2 mg/L and ≤0.25/1 mg/L, respectively). Omadacycline showed no improvement relative to classic tetracyclines (MIC/MIC values of 8/32 mg/L and 8/16 mg/L for Enterobacterales and A. baumannii, respectively). Resistance mechanisms in Enterobacterales included efflux pumps (AcrAB-TolC, OqxAB) and mutation in their regulatory genes. In A. baumannii, adeS gene mutations and adeABC upregulation decreased tigecycline activity. The prevalent sequence types with reduced susceptibility to eravacycline and tigecycline were ST307 in K. pneumoniae and ST2 in A. baumannii.
Eravacycline remains a key agent for the treatment of bacterial infections exhibiting promising efficacy against multidrug-resistant pathogens. As an empirical antibiotic it could be a good alternative for severe infections caused by CPE or CRAB, however, its clinical use is limited by the absence of standardized breakpoints. Resistance mechanisms, including efflux pumps and gene mutations, vary among isolates. High-risk clones like K. pneumoniae ST307 and A. baumannii ST2 underscore the necessity of prudent antibiotic use.
多重耐药菌的增加对临床微生物学提出了挑战。替加环素、依拉环素和奥马环素对耐碳青霉烯类肠杆菌科细菌和鲍曼不动杆菌显示出良好前景。本研究评估了它们的活性及耐药机制。
对西班牙两个多中心收集的经全基因组测序(WGS)鉴定的产碳青霉烯酶肠杆菌科细菌(n = 399)和鲍曼不动杆菌(n = 118)进行检测。测定了替加环素、依拉环素、奥马环素和经典四环素的最低抑菌浓度(MIC)。通过WGS引导的耐药基因组分析、表达研究、外排泵抑制和克隆试验确定潜在的耐药机制。
替加环素和依拉环素对整个肠杆菌科细菌组显示出最高活性(MIC/MIC分别为0.5/1mg/L和1/2mg/L),对鲍曼不动杆菌的活性也最高(MIC/MIC分别为1/2mg/L和≤0.25/1mg/L)。奥马环素相对于经典四环素没有显示出优势(肠杆菌科细菌和鲍曼不动杆菌的MIC/MIC值分别为8/32mg/L和8/16mg/L)。肠杆菌科细菌的耐药机制包括外排泵(AcrAB-TolC、OqxAB)及其调控基因突变。在鲍曼不动杆菌中,adeS基因突变和adeABC上调降低了替加环素的活性。对依拉环素和替加环素敏感性降低的常见序列类型在肺炎克雷伯菌中为ST307,在鲍曼不动杆菌中为ST2。
依拉环素仍然是治疗细菌感染的关键药物,对多重耐药病原体显示出有前景的疗效。作为经验性抗生素,它可能是治疗由耐碳青霉烯类肠杆菌科细菌(CPE)或耐碳青霉烯类鲍曼不动杆菌(CRAB)引起的严重感染的良好替代药物,然而,其临床应用受到缺乏标准化断点的限制。包括外排泵和基因突变在内的耐药机制在不同分离株中有所不同。像肺炎克雷伯菌ST307和鲍曼不动杆菌ST2这样的高风险克隆强调了谨慎使用抗生素的必要性。